Ann Steagall

Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II Trial

Mark A. Socinski, Ann Steagall, Heidi H. Gillenwater · Cancer Investigation · 1999 · 48 citations

Medicine, Oncology, Pharmacology +15

A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.

Matthew M. Graham, Stephen A. Bernard, Ann Steagall et al. · PubMed · 1995 · 23 citations

Medicine, Oncology, Pharmacology +17

A phase I trial of α‐interferon in combination with pentostatin in hematologic malignancies

Stephen A. Bernard, Parkash S. Gill, Peter J. Rosen et al. · Medical and Pediatric Oncology · 1991 · 15 citations

Medicine, Oncology, Pharmacology +11

Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.

Mark A. Socinski, Jeffrey A. Clark, Jan Halle et al. · PubMed · 1997 · 14 citations

Medicine, Oncology, Radiation Oncology +13

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients

Mark A. Socinski, Paul N. Mudd, Kristine M. Radomski et al. · Anti-Cancer Drugs · 1998 · 10 citations

Pharmacy, Oncology, Pharmacokinetics +17